FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589244089> ?p ?o ?g. }

• W2589244089 endingPage "205" @default.
• W2589244089 startingPage "205" @default.
• W2589244089 abstract "205 Background: Lapatinib causes diarrhea in about 40-50% of patients treated with it for HER-2 positive breast cancer. It is the major dose and treatment limiting toxicity of lapatinib. Methods: This is a retrospective review of a cohort of patients treated with lapatinib for HER2 positive breast cancer at the Kirklin clinic at the University of Alabama at Birmingham from January 1, 2009 through September 30, 2013. Loperamide 2-8mg before lapatinib dose was recommended for prophylaxis in patients who developed clinically significant diarrhea. Additional doses of loperamide were used if needed. Results: 44 eligible patients were identified, 7 had stage IA, 10 had IIA, 7 had IIB, 5 had IIIA, 5 had IIIB and 6 had stage IV disease. Median age was 52 years (28-72 years) with 75% Caucasians. Starting dose of lapatinib was 1000mg oral daily. Overall 33 patients experienced diarrhea. 14 had NCI grade I, 5 had grade II, 10 had grade III and 3 had grade IV diarrhea. Other side effects encountered included rash, nausea, vomiting, LFT elevation, fatigue and allergic reaction. 17/33 patients received prophylactic loperamide. Median treatment duration with lapatinib for all patients was 6 months, range 1-60 months for patients receiving prophylactic loperamide and 1-22 months for others. 12/17 patients who received prophylactic loperamide had early improvement in diarrhea to NCI grade I or less vs. 4/16 for others. 5/17 patients who received prophylactic antidiarrheals required dose reduction due to diarrhea vs. 8/16 for others. Grade III and IV diarrhea was more common in standard treatment patients (8 vs. 5). 14 patients did not complete expected treatment duration, 5 due to diarrhea, all of whom had not received prophylactic antidiarrheals. Conclusions: Our study suggests that the use of prophylactic antidiarrheal treatment with lapatinib is possibly an effective strategy in getting patient to their therapy goals without interruptions or dose adjustments. The discontinuation rate and dose reduction rate in our population is lower than previously reported. Larger prospective studies will be of interest to evaluate this strategy further. Similar strategy could be applied to other agents causing diarrhea." @default.
• W2589244089 created "2017-03-03" @default.
• W2589244089 creator A5006042406 @default.
• W2589244089 creator A5068287599 @default.
• W2589244089 creator A5089412355 @default.
• W2589244089 date "2015-10-10" @default.
• W2589244089 modified "2023-10-14" @default.
• W2589244089 title "Prophylactic use of antidiarrheal agents to control diarrhea associated with lapatinib therapy in breast cancer patients." @default.
• W2589244089 doi "https://doi.org/10.1200/jco.2015.33.29_suppl.205" @default.
• W2589244089 hasPublicationYear "2015" @default.
• W2589244089 type Work @default.
• W2589244089 sameAs 2589244089 @default.
• W2589244089 citedByCount "3" @default.
• W2589244089 countsByYear W25892440892019 @default.
• W2589244089 countsByYear W25892440892020 @default.
• W2589244089 countsByYear W25892440892022 @default.
• W2589244089 crossrefType "journal-article" @default.
• W2589244089 hasAuthorship W2589244089A5006042406 @default.
• W2589244089 hasAuthorship W2589244089A5068287599 @default.
• W2589244089 hasAuthorship W2589244089A5089412355 @default.
• W2589244089 hasConcept C121608353 @default.
• W2589244089 hasConcept C126322002 @default.
• W2589244089 hasConcept C141071460 @default.
• W2589244089 hasConcept C2777329042 @default.
• W2589244089 hasConcept C2777573665 @default.
• W2589244089 hasConcept C2779786085 @default.
• W2589244089 hasConcept C2779802037 @default.
• W2589244089 hasConcept C2780580376 @default.
• W2589244089 hasConcept C2780852908 @default.
• W2589244089 hasConcept C530470458 @default.
• W2589244089 hasConcept C71924100 @default.
• W2589244089 hasConcept C90924648 @default.
• W2589244089 hasConceptScore W2589244089C121608353 @default.
• W2589244089 hasConceptScore W2589244089C126322002 @default.
• W2589244089 hasConceptScore W2589244089C141071460 @default.
• W2589244089 hasConceptScore W2589244089C2777329042 @default.
• W2589244089 hasConceptScore W2589244089C2777573665 @default.
• W2589244089 hasConceptScore W2589244089C2779786085 @default.
• W2589244089 hasConceptScore W2589244089C2779802037 @default.
• W2589244089 hasConceptScore W2589244089C2780580376 @default.
• W2589244089 hasConceptScore W2589244089C2780852908 @default.
• W2589244089 hasConceptScore W2589244089C530470458 @default.
• W2589244089 hasConceptScore W2589244089C71924100 @default.
• W2589244089 hasConceptScore W2589244089C90924648 @default.
• W2589244089 hasIssue "29_suppl" @default.
• W2589244089 hasLocation W25892440891 @default.
• W2589244089 hasOpenAccess W2589244089 @default.
• W2589244089 hasPrimaryLocation W25892440891 @default.
• W2589244089 hasRelatedWork W2002011010 @default.
• W2589244089 hasRelatedWork W2019402297 @default.
• W2589244089 hasRelatedWork W2030949051 @default.
• W2589244089 hasRelatedWork W2031311309 @default.
• W2589244089 hasRelatedWork W2041128529 @default.
• W2589244089 hasRelatedWork W2320562621 @default.
• W2589244089 hasRelatedWork W2468258954 @default.
• W2589244089 hasRelatedWork W2751339230 @default.
• W2589244089 hasRelatedWork W3142684436 @default.
• W2589244089 hasRelatedWork W3200163803 @default.
• W2589244089 hasVolume "33" @default.
• W2589244089 isParatext "false" @default.
• W2589244089 isRetracted "false" @default.
• W2589244089 magId "2589244089" @default.
• W2589244089 workType "article" @default.